Innogenetics - Kapitaals ronde voor 34 miljoen €

Innogenetics raises €34.5 million in private placement with KBC Securities
Gent (Belgium) – March 24, 2005, Innogenetics, a Belgium-based international biopharmaceutical company focused on specialty diagnostics and therapeutic vaccines, today announces that it has raised €34,518,726.32 through the private placement of 2,660,216 new shares with institutional investors at a price of €12.60 per share and through the placement of 69,784 new shares with one of its reference shareholders, CRI BVBA at a price of €14.33 per share.
Subject to certain conditions that are standard for this type of transaction, the shares will be issued and paid for on March 31, 2005. Immediately thereafter, Innogenetics will apply for admission of the new shares on Euronext Brussels.
The offer has been coordinated and managed by KBC Securities, lead manager and sole bookrunner. The demand for new shares is oversubscribed.
Frank Morich, Chief Executive Officer of Innogenetics, commented: “We are very pleased with the outcome of this successful placement, thus confirming the trust of our shareholders and the financial community in Innogenetics’ business model. The proceeds of this capital raising will be instrumental in further strengthening our Specialty Diagnostics business.”